Lilly Stock Slips On Mixed Bag Q2 Earnings, Cuts FY21 Sales Outlook For COVID-19 TherapiesBenzinga • 08/03/21
Eli Lilly's stock falls after profit comes up short of expectations, while revenue beatMarket Watch • 08/03/21
Lilly Delivers Strong Second-Quarter 2021 Financial Results, Updates 2021 Financial GuidancePRNewsWire • 08/03/21
Lilly and Incyte's baricitinib reduced deaths among patients with COVID-19 receiving invasive mechanical ventilationPRNewsWire • 08/03/21
Lilly's Donanemab Lowers Alzheimer's-Associated Biomarkers In Patients With Early DiseaseBenzinga • 07/30/21
Lilly releases donanemab data that demonstrated relationship between reduction of amyloid plaque and slowing of cognitive declinePRNewsWire • 07/29/21
FDA broadens existing emergency use of Lilly and Incyte's baricitinib in patients hospitalized with COVID-19 requiring oxygenPRNewsWire • 07/29/21
Lilly, Kumquat Biosciences Team Up To Discover, Develop Immuno-Oncology CandidatesBenzinga • 07/29/21
Lilly and Kumquat Biosciences Announce Collaboration to Discover and Develop Novel Small Molecules that Stimulate Tumor-Specific Immune ResponsesPRNewsWire • 07/29/21
Domino's, Eli Lilly, McDonald's, Merck and More Tuesday Afternoon Analyst Upgrades and Downgrades24/7 Wall Street • 07/27/21
Lilly Confirms Date and Conference Call for Second-Quarter 2021 Financial Results AnnouncementPRNewsWire • 07/22/21